Clinical trials: Endocrine System Disorder
Diabete Mellitus
Clinical Trial to Evaluate the Efficacy and Safety of DA-5218 in Patients With Type 2 Diabetes
This study is a multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of DA-5218 in patients with type 2 diabetes who have inadequate glycemic control with…
- Trial name
- NCT07229534
- Testing
- DA-5218, DA-5218-C
- Volunteers
- 238 people
- Sponsor
- Dong-A ST Co., Ltd.
Diabetes Mellitus, Type 2
4 Weeks Treatment of Type II Diabetic Patients With BI 44847
The primary objective of the current study is to investigate the safety and tolerability of BI 44847 in male and female patients with type 2 diabetes following oral administration of repeated doses of 100 mg b.i.d, 400 mg b.i.d.
- Trial name
- NCT00558909
- Testing
- BI 44847
- Where
- 4 sites in Germany, Netherlands
- Volunteers
- 80 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Comparison of Nutritional Products for People With Type 2 Diabetes
Part A: To compare the glucose and insulin responses of a standard tube feeding product to that of a diabetes-specific tube feeding product in individuals with type 2 diabetes.
- Trial name
- NCT00520065
- Testing
- enteral nutritional formula, Diabetes specific enteral product
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Abbott Nutrition
Pancreatic Cancer
A Study to Test the Effectiveness of Virulizin® Given in Combination With Standard Chemotherapy for Pancreatic Cancer
Virulizin is an immunotherapy drug preparation that is thought to stimulate the patient's immune system, which in turn may slow the growth of tumors. It is presented in vials as a sterile preparation for IM injection.
- Trial name
- NCT00040092
- Testing
- Virulizin®
- Volunteers
- 400 people
- Sponsor
- Aptose Biosciences Inc.
Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene).
- Trial name
- NCT05241834
- Testing
- LOXO-260
- Where
- 16 sites in United States, France
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
End Stage Kidney Disease (ESKD)
A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)
This is a phase 1b, partial-blind (Sponsor unblinded), randomized, multicenter, placebo-controlled study. The primary objective of this study is to evaluate the pharmacokinetics (PK) of CSL300 after single and multiple doses in…
- Trial name
- NCT07619820
- Testing
- CSL300
- Where
- China
- Volunteers
- 24 people
- Sponsor
- CSL Behring
Type 1 Diabetes
A Single Bolus, 12-hour Euglycemic Clamp Study of the Safety, Pharmacokinetics (PK) and Glucodynamics (GD) of Intraperitoneal (IP) Portal Insulin U-500
The goal of this clinical trial is to assess the safety of a new U500 insulin formulation and to determine how rapidly it is absorbed and how long it takes to act when administered intraperitoneally.
- Trial name
- NCT07341373
- Testing
- Portal Insulin U-500, Humulin R U-500, Lyumjev U-100 Insulin
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Portal Diabetes, Inc.
Malignant Solid Tumour, Ovarian Cancer
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Overall Design: This is a multicenter, open-label, Phase 1/2 study which will be conducted in three arms (as described below). Each arm will be conducted in two parts: a Phase 1 part which will include dose escalation and a Phase…
- Conditions
- Malignant Solid Tumour, Ovarian Cancer, Triple Negative Breast Cancer, Advanced Melanoma
- Trial name
- NCT01618136
- Testing
- E7449 alone, E7449 plus TMZ, E7449 plus carboplatin and paclitaxel
- Where
- 2 sites in United Kingdom
- Volunteers
- 41 people
- Sponsor
- Eisai Limited
Diabetes Mellitus, Type 2, Diabetes Mellitus
Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients
The study is designed to approve non-inferior efficacy and safety of Insulin Lispro Biphasic 25 ("Geropharm") compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients.
- Trial name
- NCT04023344
- Testing
- Humalog Mix25, Insulin Lispro Biphasic 25
- Where
- 18 sites in Russia
- Volunteers
- 210 people
- Sponsor
- Geropharm
Metastatic Pancreatic Cancer
Saltikva for Metastatic Pancreatic Cancer
Objectives: Assess the efficacy of multiple dose oral administration of Saltikva, an attenuated strain of Salmonella Typhimurium expressing IL-2, in patients with metastatic pancreatic cancer on standard chemotherapy (either…
- Trial name
- NCT04589234
- Testing
- Salmonella-IL2, FOLFIRINOX Alone (Historical Controls), Gemcitabine/Abraxane Alone (Historical Controls)
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Salspera LLC
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
This trial is conducted in Asia and Japan. The aim of this trial is to compare insulin degludec (NN1250) with insulin glargine both combined with oral antidiabetic drugs (OADs) in subjects with type 2 diabetes never treated with…
- Trial name
- BEGIN™ (NCT01059799)
- Testing
- insulin degludec, insulin glargine
- Where
- 53 sites in Hong Kong, Japan and 4 more
- Volunteers
- 435 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to compare the pharmacodynamics and pharmacokinetics after a single dose of biphasic insulin aspart 30, biphasic insulin aspart 50, biphasic insulin aspart 70 and…
- Trial name
- NCT01536028
- Testing
- biphasic insulin aspart 30, biphasic insulin aspart 50, biphasic insulin aspart 70
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Safety Evaluation of MiniMed™ 780G System With DS5 CGM in Children
The purpose of this study is to evaluate the safety of the MiniMed 780G insulin pump used in combination with the DS5 CGM in type 1 pediatric subjects (2-6 years of age) in a home setting.
- Trial name
- SUCCEED2 (NCT06604871)
- Testing
- Insulin Pump with Continuous Glucose Monitoring
- Where
- 8 sites in United States
- Volunteers
- 56 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 2
A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin
The purpose of this study is to assess the effect of canagliflozin (JNJ-28431754) compared to placebo in the treatment of participants with Type 2 Diabetes Mellitus (T2DM), who have inadequate glycemic control on maximally or…
- Trial name
- NCT02025907
- Testing
- Canagliflozin, 100 mg, Canagliflozin, 300 mg
- Where
- 57 sites in United States, Australia and 3 more
- Volunteers
- 218 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes
A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 Diabetes
This study is a multi-center, randomized, open-label, parallel, positive-controlled registered clinical study,to evaluate the efficacy and safety of insulin degludec injection developed by Chia Tai Tianqing Pharmaceutical Group…
- Trial name
- NCT04955834
- Testing
- Insulin degludec injection, Tresiba®
- Where
- 2 sites in China
- Volunteers
- 344 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Gingival Inflammation in Diabetic Patients
Herbal Periodontal Patch (THPP) for Gingival Inflammation in Diabetics
Diabetes increases the incidence and severity of periodontal inflammation and disease, and periodontal disease causes an increase in the severity of diabetes by worsening glycemic control and increasing insulin resistance.The…
- Trial name
- NCT00731432
- Testing
- Transmucosal Herbal Periodontal Patch (THPP)
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Izun Pharma Ltd
Diabetes Mellitus
Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin
A multicenter, randomized, double-blind, placebo-controlled trial will assess the effects of twice-daily subcutaneous injection with exenatide versus treatment with matching placebo injection on abdominal visceral fat content.
- Trial name
- NCT00701935
- Testing
- exenatide
- Where
- 17 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- AstraZeneca
PreDiabetes
Prevention of Microvascular Complications in Prediabetes e-PREDICE Study
Background: A significant proportion of pre-diabetics, show macro and micro vascular complications associated with hyperglycaemia.
- Trial name
- ePREDICE (NCT03222765)
- Where
- Spain
- Volunteers
- 1,000 people
- Sponsor
- Evidem Consultores SL
Diabetic Retinopathy
A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)
Diabetic retinopathy (DR) is a diabetes complication caused by damage to the small blood vessels inside the retina at the back of the eye. Diabetic retinopathy may cause mild vision problems or eventually blindness.
- Trial name
- ReFineDR (NCT04477707)
- Testing
- Finerenone (BAY94-8862)
- Where
- 62 sites in United States, Argentina and 13 more
- Volunteers
- 206 people
- Sponsor
- Bayer
Type 2 Diabetes
A Pharmacokinetic Study Comparing the Liraglutide Injection (RD12014) and Victoza® in Healthy Chinese Subjects
To evaluate the pharmacokinetics similarity between the liraglutide injection (RD12014) produced by Sunshine Lake Pharma Co., Ltd.
- Trial name
- NCT05294536
- Testing
- Liraglutide injection,RD12014, Liraglutide injection,Victoza
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.